In a way, the coming year isn't a big one for patent expirations. The total
amount of sales jeopardized by patent expirations is $34 billion. That's more
than the $28 billion this year, but far less than the $55 billion that hit in
2012. As for 2015? Forget about it. That year, products worth $66 billion will
lose IP protection.
Plus, the drugs facing new competition won't all take a big hit in 2014. In
fact, EvaluatePharma figures that the products newly open to generic
competition will only lose $13 billion off their previous totals.